A lab technician inspects filled vials of investigational coronavirus disease (COVID-19) treatment drug remdesivir at a Gilead Sciences facility in La Verne, California, U.S. March 11, 2020. Picture taken March 11, 2020.
Gilead Sciences Inc | Reuters
Gilead Sciences published new data Friday on its antiviral drug remdesivir that shows it reduced the risk of death for coronavirus patients by 62% compared with standard care alone.
The findings are being presented at the Virtual Covid-19 Conference as part of the 23rd International AIDS Conference, the company said.
This is breaking news. Please check back for updates.
This article was originally published by Cnbc.com. Read the original article here.